Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt repayments
Ratios

Avanos Medical (AVNS) EBIAT (2016 - 2026)

Avanos Medical's EBIAT history spans 13 years, with the latest figure at -$1.3 million for Q4 2025.

  • On a quarterly basis, EBIAT rose 99.67% to -$1.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$72.9 million, a 81.27% increase, with the full-year FY2025 number at -$72.9 million, up 81.13% from a year prior.
  • EBIAT hit -$1.3 million in Q4 2025 for Avanos Medical, up from -$1.4 million in the prior quarter.
  • Over the last five years, EBIAT for AVNS hit a ceiling of $38.7 million in Q4 2022 and a floor of -$397.0 million in Q4 2024.
  • Historically, EBIAT has averaged -$27.6 million across 5 years, with a median of -$1.3 million in 2025.
  • Biggest five-year swings in EBIAT: skyrocketed 1383.33% in 2021 and later crashed 1886.05% in 2025.
  • Tracing AVNS's EBIAT over 5 years: stood at -$25.7 million in 2021, then skyrocketed by 250.58% to $38.7 million in 2022, then tumbled by 205.68% to -$40.9 million in 2023, then crashed by 870.66% to -$397.0 million in 2024, then skyrocketed by 99.67% to -$1.3 million in 2025.
  • Business Quant data shows EBIAT for AVNS at -$1.3 million in Q4 2025, -$1.4 million in Q3 2025, and -$76.8 million in Q2 2025.